- What is Chronic immunotoxicity of immune checkpoint inhibitors?
- This anti-aging medicine has gone astray: Chronic inflammation leads to a decrease in NAD+
- FDA Approved Treatment Funded by Ice Bucket Challenge Donors
- Similar to HIV: Another deadly monkey virus may spread to humans
- 2022 Nobel Prize Winner Paper: The risk of severe COVID-19 is inherited from Neanderthals
- Breakthrough method ‘starves’ highly lethal cancer tumors and eradicates them
PertuzuHER2-positive targeted drugs for breast cancer
- New breakthrough in CAR-T cell therapy: Lupus erythematosus patients achieved treatment-free remission for up to 17 months
- Is the new COVID Omicron variant BA.4.6 more contagious?
- How long can the patient live after heart stent surgery?
- First time: Systemic multi-organ recovery after death
- Where do the bacteria in the human gut come from?
HER2-positive targeted drugs for breast cancer.
Which types of cancer patients are suitable for breast cancer targeted drugs? Breast cancer can be said to be a relatively low malignant tumor among all malignant tumors.
It is not as malignant and mortality as lung cancer, stomach cancer, and liver cancer.
As long as early breast cancer is found, the cure rate is still relatively high through active treatment.
For breast cancer treatment, the past few decades have been nothing more than surgery, radiotherapy and chemotherapy.
With the development of science and technology, breast cancer targeted drugs have gradually appeared in many breast cancers due to their advantages such as less side effects than chemotherapy.
The patient’s treatment plan.
Which types of cancer patients are suitable for breast cancer targeted drugs?
Breast cancer patients can actually be divided into several categories according to molecular classification, that is, according to the expression of the three proteins of ER, PR and HER2 in immunohistochemistry, there will be Luminal A subtypes (ER+/PR+, HER2–), Luminal Breast cancers of subtype B (ER+/PR+, HER2+ or ki67 are highly expressed), HER2 (ER–/PR–/HER2+) and triple-negative (ER–/PR–/HER2–) breast cancers.
Let’s take a look at HER2-positive breast cancer patients. Under normal circumstances, the expression of breast cells is very low.
This type of breast cancer is overexpressed by breast cancer HER2 protein, which is a signal for growth, which causes the breast. Excessive proliferation of tumor cells.
Therefore, this kind of tumor is more malignant than endocrine breast cancer and reproduces faster.
With the advancement of medical technology, for this type of patients, drugs targeting HER2 can be used to block HER2 activity and selectively kill cancer cells with high HER2 expression.
Let’s take a look at what are the HER2-positive breast cancer targeted drugs?
1. Trastuzumab (Herceptin)
Approved in 1998, it is also the earliest HER2-positive targeted drug. It needs to be used for about 1 year, but unfortunately, this drug is also prone to drug resistance.
Pertuzumab was launched in the United States in June 2012, blocked the heterodimerization of HER2 and other HER receptors by binding to HER2, thereby slowing the growth of tumors. Pertuzumab combined with Herceptin combined with chemotherapy, compared with Herceptin combined with chemotherapy, can extend the median overall survival of advanced patients by 15.7 months.
3. Hersele, Kadcyla:
A new type of TDM-1 drug, a drug conjugated with trastuzumab and chemical drugs.
Related trials have shown that it can reduce the risk of disease progression and death by 50%. It has been approved by the State Food and Drug Administration in early 2020 Listed.
4. Lenatinib maleate:
This drug is the first “intensive adjuvant therapy” approved by the FDA for HER2-positive early breast cancer patients who have received adjuvant trastuzumab (Herceptin) therapy.
This drug is developed drug by Chinese company: Hengrui Medicines.
It was approved by the China National Medical Products Administration for the treatment of advanced HER2-positive breast cancer in 2018 .
In the 2019 CSCO BC guidelines, pyrrotinib is recommended for the second-line treatment of advanced HER2-positive breast cancer with a level of evidence of 2A. The guidelines introduce:
- For patients with advanced HER2-positive breast cancer who have failed HER2 treatment, pyrrotinib combined with capecitabine is the only level I recommendation (1A), while T-DM1 monotherapy and lapatinib combined with capecitabine are recommended Level II recommendation;
- It can also be considered for HER2-positive patients with brain metastases;
- In the HER2-positive treatment plan, follow-up treatment with or without trastuzumab;
- Among HRE2-positive patients, for patients who have used or have used or can use trastuzumab again, taxanes + H + Pertuzumab) regimen and TXH (taxanes + capecitabine + H) All are 1A grade recommendation;
- The pyrrotinib + capecitabine regimen is also recommended.
The above is the introduction of several breast cancer targeted drugs, but each drug will have certain toxic side effects.
Whether patients are suitable for targeted drugs, you also need to ask a doctor for relevant tests and physical assessments before they can be treated. Patients must not take medicines privately to avoid unnecessary side effects and delay in treatment.
HER2-positive targeted drugs for breast cancer
(source:chinanet, reference only)